Synthetic Biologics Inc. announced the expansion of its Clinical Advisory Board created to support development of SYN-010, the company's statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS). The C-IBS CAB, chaired by Mark Pimentel, M.D., Director of the GI Motility Program and Laboratory at Cedars-Sinai Medical Center, is strengthened by the addition of four new members. William Chey, M.D., is a Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan.

Dr. Chey's clinical and research interests include: diagnosis and treatment of irritable bowel syndrome (IBS), constipation, fecal incontinence; gastroesophageal reflux disease (GERD), and "H. pylori" infection. Gail M. Comer, M.D., a board-certified gastroenterologist and hepatologist, has more than 16 years of experience in the pharmaceutical industry, having spent seven years at Abbott Laboratories as a Medical Director, six years in clinical development at Wyeth Research as Senior Medical Director, Senior Director of the BioTherapeutics Research Unit at Pfizer. She also served as the Chief Medical Officer at Synergy Pharmaceuticals before starting her own consulting business.

Anthony J. Lembo, M.D., is Associate Professor of Medicine at Harvard Medical School. He also serves as the Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center's (BIDMC) Division of Gastroenterology in Boston, MA. Philip Schoenfeld, M.D., MSEd, MSc, is Professor of Medicine at the University of Michigan School of Medicine, Director of the University's Gastrointestinal Epidemiology Training Program, and staff physician in UM's Specialized Functional Bowel Disorder Program.